Amgen Highlights The Versatility Of The BiTE ® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO® Investigational AMG 212 (Pasotuxizumab) Phase 1 Study Explores Use of BiTE Platform in a Solid Tumor THOUSAND OAKS, Calif., June 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Data presented included updated investigational AMG 420 safety and efficacy results in patients with relapsed and/or refractory multiple ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news